Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

205.40
-2.3700-1.14%
Post-market: 205.400.00000.00%19:34 EDT
Volume:293.23K
Turnover:60.42M
Market Cap:10.76B
PE:-54.50
High:208.09
Open:207.00
Low:205.09
Close:207.77
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:0.50
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:129.15
PE(LYR):-55.78

Loading ...

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Rising Revenue And Widening Net Losses

Simply Wall St.
·
Yesterday

Axsome Therapeutics (AXSM) Stock Still Trades Below Fair Value On Sales

Simply Wall St.
·
Aug 21

UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating

MT Newswires Live
·
Aug 12

Liquidia Q2 Revenue Jumps on Yutrepia Sales

Reuters
·
Aug 12

Axsome Therapeutics (AXSM) Receives a Buy from Mizuho Securities

TIPRANKS
·
Aug 12

Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says

MT Newswires Live
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Axsome Therapeutics (AXSM) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Aug 11

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Benzinga Earnings
·
Aug 11

Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital

TIPRANKS
·
Aug 11

Axsome Therapeutics Price Target Raised to $256.00/Share from $255.00 by Wells Fargo

Dow Jones
·
Aug 11

Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley

TIPRANKS
·
Aug 11

Fennec Pharmaceuticals Q2 Sales Rise on Pedmark Demand

Reuters
·
Aug 11

RBC Adjusts PT on Axsome Therapeutics to $297 From $304, Maintains Outperform Rating

MT Newswires Live
·
Aug 11

U.S. Research Roundup-Accendra Health, Celestica, Sionna Therapeutics

Reuters
·
Aug 11

Faster Revenue Growth With Wider Losses Might Change The Case For Investing In Axsome (AXSM)

Simply Wall St.
·
Aug 11

Movement Alert|Axsome Therapeutics Rises 5.01% in Regular Trading, Q2 Revenue Up 46% YoY as Stock Recovers Pre-Market Losses

Market Focus
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Aquestive Therapeutics (AQST) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Aug 11

Axsome Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Sector Update: Healthcare Stocks Edge Higher Premarket Monday

MT Newswires Live
·
Aug 10

Axsome Therapeutics Shares Reverse Course Premarket; Last up 2.2%

THOMSON REUTERS
·
Aug 10